Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 256

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1B
Chunk 256
---
 STOCKHOLDERS’ DEFICIT 

    Current liabilities: 

    Accounts payable 
    $134,865  
    $118,478 
  
    Accrued compensation 
     3,767,652  
     3,184,911 
  
    Accrued consulting 
     787,903  
     787,903 
  
    Accrued expenses and other 
     646,850  
     641,763 
  
    Loan payable 
     200,000  
     – 
  
    Total current liabilities 
     5,537,270  
     4,733,055 

    Convertible notes, net 
     1,392,515  
     1,317,536 

    Total liabilities 
     6,929,785  
     6,050,591 

    Commitments and contingencies 
     –  

    Stockholders’ deficit: 

    Preferred stock, $0.00001 par value; 5,000,000 shares authorized: 
     –  

    Series A Convertible Voting Preferred Stock; 630,000 shares designated; no shares issued and outstanding 
     –  
     – 
  
    Series B Convertible Voting Preferred Stock; 70,000 shares designated; 70,000 shares issued and outstanding 
     1  
     1 
  
    Common stock, $0.00001 par value: 100,000,000 shares authorized: 7,242,137 shares issued and outstanding 
     72  
     72 
  
    Additional paid-in capital 
     2,050,073  
     2,045,206 
  
    Accumulated deficit 
     (8,838,320) 
     (7,916,337)
  
    Total stockholders’ deficit 
     (6,788,174) 
     (5,871,058)
  
    Total liabilities and stockholders’ deficit 
    $141,611  
    $179,533 

See accompanying notes to consolidated financial statements.

 F-4 

Mosaic ImmunoEngineering, Inc.

Consolidated Statements of Operations

    Year Ended December 31, 

    2024  
    2023 
  
    Operating expenses: 

    Research and development 
    $183,867  
    $435